Literature DB >> 10617694

Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes.

E G Schuetz1, D R Umbenhauer, K Yasuda, C Brimer, L Nguyen, M V Relling, J D Schuetz, A H Schinkel.   

Abstract

We hypothesized that the drug efflux protein P-glycoprotein (Pgp), the product of the multidrug resistance gene MDR1, might influence hepatic expression of CYP3A or other cytochromes P-450 (P-450s) because Pgp can transport endogenous regulators of these cytochromes. We began with variants of a CF-1 mouse strain containing a defective mdr1a gene that is inherited in a Mendelian fashion. The amount of CYP3A protein in liver was inversely related to the gene dose of the normal mdr1a allele in these mice. mdr1a knockout mice of either mixed (FVB x 129/Ola) or pure FVB genetic background and housed in Amsterdam display an increased expression of CYP2B and CYP3A proteins. However, because mdr1a ablation causes a compensatory increase in hepatic mdr1b (which can efflux intracellular glucocorticoids), we reasoned that mdr1b might mask the overall effect of mdr1a absence on P-450 gene expression. Targeted inactivation of the mdr1b gene increased P-450 expression, but the effect was modest compared with mdr1a ablation. Mice nullizygous for both mdr1a and mdr1b-type Pgps and kept in Amsterdam had dramatically increased levels of CYP3A protein as well as other P-450s examined and of the electron donor P-450 reductase. Consistent with the protein results, CYP3A catalytic activity measured as midazolam 1'- and 4-hydroxylation in liver microsomes from these knockout mice revealed a rank order of activities with mdr1a/1b > mdr1a > mdr1b > (+/+) mice. In contrast to results in mice housed in Amsterdam, in the genetically identical mdr1a or mdr1a/1b (-/-) male mice housed in the United States, hepatic P-450 expression was unaffected by mdr1 genotype or actually showed a slight decrease in mdr1a (-/-) mice. These results provide a revealing picture of mdr1-type Pgp as an upstream regulator of hepatic P-450 expression, and demonstrate that these pharmacologically relevant phenotypes in knockout mice depend not only on the genetic make-up of the mice but also on the environment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10617694

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  22 in total

Review 1.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.

Authors:  Young Hee Choi; Ai-Ming Yu
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

3.  Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice.

Authors:  Manuela Pereira de Oliveira; Emmanuel Garcion; Nicolas Venisse; Jean-Pierre Benoit; William Couet; Jean-Christophe Olivier
Journal:  Pharm Res       Date:  2005-11       Impact factor: 4.200

4.  Hepatic bile acid metabolism and expression of cytochrome P450 and related enzymes are altered in Bsep (-/-) mice.

Authors:  Eugene Hrycay; Dana Forrest; Lin Liu; Renxue Wang; Jenny Tai; Anand Deo; Victor Ling; Stelvio Bandiera
Journal:  Mol Cell Biochem       Date:  2014-01-08       Impact factor: 3.396

5.  MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.

Authors:  Siegfried Drescher; Elke Schaeffeler; Monika Hitzl; Ute Hofmann; Matthias Schwab; Ulrich Brinkmann; Michel Eichelbaum; Martin F Fromm
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

6.  Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.

Authors:  J H Beumer; N E Franke; R Tolboom; T Buckle; H Rosing; L Lopez-Lazaro; J H M Schellens; J H Beijnen; O van Tellingen
Journal:  Invest New Drugs       Date:  2009-02-24       Impact factor: 3.850

7.  Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat.

Authors:  Sarah E Lacher; Julia N Gremaud; Kasse Skagen; Emily Steed; Rachel Dalton; Kent D Sugden; Fernando Cardozo-Pelaez; Catherine M T Sherwin; Erica L Woodahl
Journal:  J Pharmacol Exp Ther       Date:  2013-12-02       Impact factor: 4.030

8.  Genetic predictors of interindividual variability in hepatic CYP3A4 expression.

Authors:  Vishal Lamba; John C Panetta; Stephen Strom; Erin G Schuetz
Journal:  J Pharmacol Exp Ther       Date:  2009-11-24       Impact factor: 4.030

9.  Assessment of the disposition of chiral polychlorinated biphenyls in female mdr 1a/b knockout versus wild-type mice using multivariate analyses.

Authors:  Bartłomiej Milanowski; Janina Lulek; Hans-Joachim Lehmler; Izabela Kania-Korwel
Journal:  Environ Int       Date:  2009-11-17       Impact factor: 9.621

10.  Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro.

Authors:  Yasuhisa Adachi; Hiroshi Suzuki; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.